[Adjuvant chemotherapy for breast cancer and targeted therapies]

Rev Prat. 2008 Mar 15;58(5):477-8.
[Article in French]
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Antibiotics, Antineoplastic / therapeutic use
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Breast Neoplasms / surgery
  • Chemotherapy, Adjuvant
  • Cyclophosphamide / therapeutic use
  • Docetaxel
  • Doxorubicin / therapeutic use
  • Female
  • Humans
  • Neoplasm Recurrence, Local / prevention & control
  • Paclitaxel / therapeutic use
  • Proportional Hazards Models
  • Randomized Controlled Trials as Topic
  • Receptor, ErbB-2 / antagonists & inhibitors
  • Survival Analysis
  • Taxoids / therapeutic use
  • Trastuzumab

Substances

  • Antibiotics, Antineoplastic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Antineoplastic Agents, Alkylating
  • Antineoplastic Agents, Phytogenic
  • Taxoids
  • Docetaxel
  • Doxorubicin
  • Cyclophosphamide
  • Receptor, ErbB-2
  • Trastuzumab
  • Paclitaxel